Anti-Mouse CD226 (DNAM-1) [Clone 480.1] — Purified in vivo PLATINUM™ Functional Grade

Clone 480.1 is a rat monoclonal antibody widely used in vivo in mice to target and functionally manipulate murine CD226 (DNAM-1), a receptor involved in immune cell adhesion, signaling, cytotoxic activity, and lymphokine secretion by T cells and NK cells. The following summarizes key in vivo research applications for clone 480.1:

• Functional blockade of CD226 (DNAM-1): Clone 480.1 is frequently administered to mice to inhibit DNAM-1 function on T cells and NK cells, allowing researchers to investigate its role in immune cell activation, cytotoxicity against tumors or infected cells, and immune regulation during various disease models (such as cancer or infection).
• Evaluation of CD226’s costimulatory role: The antibody is used to disrupt DNAM-1-mediated costimulation, particularly to study its impact on Th1 cell differentiation and effector function in vivo. CD226 is significantly expressed on differentiated Th1 cells but not Th2 or Th0 cells.
• Modeling antitumor immune responses: By blocking DNAM-1, investigators can clarify how this receptor affects NK- and T-cell–mediated antitumor immunity in syngeneic mouse tumor models.
• Assessing immune cell trafficking and cytotoxicity: Given DNAM-1’s function in adhesion and cytotoxicity, clone 480.1 helps dissect mechanisms underlying immune cell interactions with dendritic cells, B cells, platelets, and monocytes in physiological and pathological contexts.

The antibody is notably validated for in vivo use due to its high purity, low endotoxin content, and preparation under animal-free conditions. While it is also used for flow cytometry and certain ex vivo assays, its principal in vivo application is the functional blockade (neutralization) of DNAM-1 on immune cells in mouse models to probe the receptor’s role in immunity and disease.

The antibody 480.1 is a rat anti-mouse CD226 (DNAM-1) monoclonal antibody, commonly used in immunology research involving murine T cells and NK cells. In the literature, 480.1 is most frequently used in combination with antibodies targeting functionally relevant markers on murine lymphocytes. The most commonly paired antibodies and proteins include:

• Anti-CD3: Used to identify or activate T cells, as CD3 is a part of the T cell receptor complex.
• Anti-CD4 / Anti-CD8: To distinguish helper T cells (CD4+) from cytotoxic T cells (CD8+).
• Anti-NK1.1 or Anti-CD49b (DX5): To identify and study natural killer (NK) cells.
• Anti-CD112 (Nectin-2) and Anti-CD155 (PVR): These are ligands for DNAM-1/CD226, used for functional blocking or staining to study ligand–receptor interactions.
• Anti-PD-1, Anti-CTLA-4, Anti-TIGIT, Anti-PVRIG: These immune checkpoint molecules are often analyzed together with DNAM-1 to study costimulatory and coinhibitory pathways on T and NK cells, especially in the context of tumor or infection immunity.
• Isotype controls: Essential for background control in flow cytometry studies.

Researchers may also use functional blocking or depletion antibodies (e.g., anti-CD226 for blocking DNAM-1 function in vivo or in vitro) alongside lineage and activation markers to elucidate the role of DNAM-1 in immune responses.

In addition, studies involving co-stimulatory or co-inhibitory pathways frequently co-stain or co-block with antibodies against CD28, CD40L, LAG-3, Tim-3, and others to dissect immune synapse dynamics or checkpoint blockade effects.

No evidence from the search indicates frequent co-use with specific protein drugs, but in multiplexed or cocktail immunotherapy, therapeutic antibodies may be coformulated or studied together against multiple targets for synergy (e.g., combinations against HER2, or immune checkpoint blockades).

To summarize: Anti-CD3, Anti-CD4, Anti-CD8, Anti-NK1.1, Anti-CD49b, Anti-CD112, Anti-CD155, Anti-PD-1, Anti-TIGIT, and relevant isotype controls are the most commonly used antibodies in combination with 480.1 in immunological research.

If you are seeking use in specific disease or model contexts, providing more detail (e.g., tumor, infection, autoimmunity) may help refine the most relevant co-used antibodies.

The clone 480.1 is specifically related to the anti-mouse CD226 (DNAM-1) antibody, which targets a crucial adhesion molecule involved in lymphocyte signaling and cytotoxicity. However, there are no specific citations in the provided search results that directly mention the key findings from clone 480.1 in scientific literature.

Based on the information available, we can infer that CD226 (DNAM-1) plays a significant role in immune responses, particularly in the activation of cytotoxic lymphocytes and as a costimulatory molecule for Th1 cells. It interacts with PVR (CD155) and NECTIN2 (CD112) on cell surfaces, which are important for intercellular adhesion and immune cell function.

For precise key findings related to clone 480.1, more specific scientific literature would be required. Generally, research involving DNAM-1 often focuses on its role in enhancing immune responses and its potential applications in immunotherapy.

Unfortunately, the search results do not provide specific information on the dosing regimens of clone 480.1 across different mouse models. Clone 480.1 is mentioned in the context of intracellular staining for mouse CD226, but details on its dosing regimen are not available in the provided sources.

However, when studying dosing regimens in mouse models, several factors typically influence the dosing strategy, including the target antigen, the specific application (e.g., cancer immunotherapy, infection models), the route of administration (often intraperitoneal), and the required frequency of administration. For similar antibodies targeting immune checkpoints or other cell surface markers, dosing regimens can vary widely depending on these factors. For example, antibodies like RMP1-14 (anti-PD-1) are commonly dosed at 200-500 μg per mouse, administered every 3-4 days via intraperitoneal injection.

To determine the optimal dosing regimen for clone 480.1, it would be necessary to consult specific research articles or experimental protocols that focus on this clone and its application in different mouse models. Such studies would provide detailed insights into effective dosing strategies based on experimental objectives and outcomes.